Groundbreaking Cell Therapy NRTX-1001 Promises Over 90% Seizure Reduction: A New Hope for Drug-Resistant Epilepsy Patients
Neurona Therapeutics, a clinical-stage biotherapeutics company, has presented new data from its ongoing Phase I/II clinical trial of a one-time dose of NRTX-1001 in people with drug-resistant mesial temporal lobe epilepsy (MTLE). The data shows a promising reduction in seizure frequency in the first and second patients at one year and seven-months post-treatment, respectively. The […]